FinanceCity
HealthcareNSE · BSE

GlaxoSmithkline Pharmaceuticals Ltd.

GLAXO · ISIN INE159A01016

Share price

₹2,159 +1.72%

Market capitalisation

₹36575 CrClosed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹36575 Cr

Current price

₹2,159

+1.72% today

52W high

₹3,500

52W low

₹2,088

Stock P/E

35.32

P/B ratio

16.13

02 · Per share & returns

EPS (TTM)

₹61.13

Book value

₹134

ROE

49.11%

ROA

18.50%

Dividend yield

2.69%

Beta

0.05

03 · Financials (TTM)

By the numbers

Revenue

₹3822 Cr

+2.10% YoY

EBITDA

₹1286 Cr

Net profit

₹1036 Cr

+5.70% YoY

Profit margin

27.11%

Operating margin

34.42%

Total debt

₹33.27 Cr

Total cash

₹2757 Cr

Debt / equity

0.01x

Current ratio

2.03x

Payout ratio

68.68%

04 · Analyst view

Target price

₹2,970

Upside

+37.55%

Consensus

BUY

Analysts

4

05 · Shareholding pattern

Who owns GLAXO?

  • Promoters

    75.00%

    Founders & promoter group

  • Institutions

    8.52%

    FII + DII

  • Public

    16.48%

    Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol
GLAXO
Exchange
NSE · BSE
CIN
ISIN
INE159A01016
BSE code
500660
Sector
Healthcare
Industry
Healthcare
Face value
₹10
Listing date
14 Dec 2000
Employees
3,103
Headquarters
Mumbai, India

07 · About

What is GlaxoSmithkline Pharmaceuticals Ltd.?

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states; Flutivate, a skin cream for adults, children, and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is based in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

08 · Common questions

Frequently asked

What is the CIN of GlaxoSmithkline Pharmaceuticals Ltd.?+

The Corporate Identity Number for GlaxoSmithkline Pharmaceuticals Ltd. is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of GlaxoSmithkline Pharmaceuticals Ltd.?+

Promoter holding in GLAXO is approximately 75.00%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of GlaxoSmithkline Pharmaceuticals Ltd.?+

GlaxoSmithkline Pharmaceuticals Ltd. (GLAXO) has a market capitalisation of approximately ₹36575 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent

Other healthcare listings

Full sector →